Madrigal Pharmaceuticals Inc [MDGL] stock prices are up 1.08% to $547.96 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The MDGL shares have gain 3.54% over the last week, with a monthly amount glided 29.28%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Madrigal Pharmaceuticals Inc [NASDAQ: MDGL] stock has seen the most recent analyst activity on November 05, 2025, when Cantor Fitzgerald upgraded its rating to an Overweight. Previously, BofA Securities upgraded its rating to Neutral on November 03, 2025, and kept the price target unchanged to $445. On October 15, 2025, Truist initiated with a Buy rating and assigned a price target of $580 on the stock. B. Riley Securities upgraded its rating to a Buy and raised its price target to $422 on February 28, 2025. H.C. Wainwright reiterated a Buy rating for this stock on February 27, 2025, and upped its price target to $405. In a note dated June 28, 2024, Cantor Fitzgerald initiated a Neutral rating.
The stock price of Madrigal Pharmaceuticals Inc [MDGL] has been fluctuating between $265.00 and $577.90 over the past year. Currently, Wall Street analysts expect the stock to reach $595.4 within the next 12 months. Madrigal Pharmaceuticals Inc [NASDAQ: MDGL] shares were valued at $547.96 at the most recent close of the market. An investor can expect a potential return of 8.66% based on the average MDGL price forecast.
Analyzing the MDGL fundamentals
The Madrigal Pharmaceuticals Inc [NASDAQ:MDGL] reported sales of 740.64M for trailing twelve months, representing a surge of 362.03%. Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -0.6%, Pretax Profit Margin comes in at -0.55%, and Net Profit Margin reading is -0.55%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -0.38 and Total Capital is -0.38. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.18.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 533.59 points at the first support level, and at 519.22 for the second support level. However, for the 1st resistance point, the stock is sitting at 563.74, and for the 2nd resistance point, it is at 579.52.
Ratios To Look Out For
It’s worth pointing out that Madrigal Pharmaceuticals Inc [NASDAQ:MDGL]’s Current Ratio is 3.44. In addition, the Quick Ratio stands at 3.26 and the Cash Ratio stands at 0.97. Considering the valuation of this stock, the price to sales ratio is 16.80, the price to book ratio is 19.88.
Transactions by insiders
Recent insider trading involved Huntsman Carole, Chief Commercial Officer, that happened on Nov 21 ’25 when 1958.0 shares were sold. Officer, Carole Huntsman completed a deal on Nov 21 ’25 to buy 894.0 shares. Meanwhile, Director Levy Richard S sold 8500.0 shares on Nov 13 ’25.
